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ABSTRACT- Fifty cases of breast carcinoma were investigated for Nm23, LPA1, Ki67 and p53 antigen expression, using 
immunohistochemical techniques. Correlation between markers was studied. Nm23 showed an inverse correlation with 
LPA1 and Ki67, and positive with p53. Nm23/LPA1presented significant (p<0.001) negative correlation with p53, but not 
difference were observed with Ki67. It can be concluded that: 1) Nm23 and LPA1 tend to be inversely correlated; 2) 
Nm23 correlates positively with p53, regardless of tumour type and patient’s hormonal status; 3) Nm23 shows a reverse 
trend in comparison with Ki67. However, more studies are needed to determinate if hormone receptors play some role in 
the inverse relationship between Nm23-LPA1 and to know the tumour type implication in these relationships. 
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INTRODUCTION 
 
 Breast cancer is a heterogeneous disease, 
comprising multiple entities associated with 
distinctive histological and biological features, 
clinical presentations and behaviours and 
responses to therapy [1;2]. Tumor cell invasion is 
a complex process and the mechanisms 
controlling the transition from ductal carcinomas in 
situ to invasive ductal carcinoma still remain 
unclear, despite research in recent years [3]. 
 Various biological makers known to be 
indicators of prognosis in breast cancer include 
growth factor receptors, estrogen receptors, p53, 
and proliferation indices like Ki67. Majority of 
breast cancer patients succumb to metastatic 
disease.  
 The molecular basis of the metastatic disease 
is not known, but activation or inactivation of 
multiple genes is involved in the various steps of 
tumour progression [4;5]. 
 The first Nm23 gene was discovered by Steeg 
et al. in 1988 [6] on the basis of its reduced 
expression in the highly metastatic murine 
myeloma cell lines, as compared to their 
nonmetastatic counterparts [6;7].  
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Similar trends were identified in other model 
systems. Low Nm23-H1 expression in human 
tumours often correlated with poor patient survival 
although it is not considered to be an independent 
prognostic factor [8]. 
 Another growing target of interest is LPA1 
(also known as EDG2), one of the receptors for 
LPA (lysophosphatidic acid). LPA1 is involved in a 
variety of physiological functions such as cellular 
proliferation, differentiation, prevention of 
apoptosis, migration, invasion, regulation of actin 
cytoskeleton, modulation of cell shape, and 
survival [9;10]. 
 The aim of this study was to investigate: 1) the 
immunohistochemical expression of Nm23 and 
LPA1 in breast carcinomas; 2) correlation 
between expressions of Nm23 with LPA1 and with 
other traditional markers in breast cancer 
diagnosis; and 3) correlation between expressions 
of Nm23/LPA1 and with other clinicopathology 
variables. 
 
MATERIALS AND METHODS 
 
 Formalin fixed paraffin-embedded blocks of 
breast lesions were retrieved from the archives of 
the Service of Pathology, Hospital Madrid 
Montepríncipe, Madrid, Spain, where classified 
the carcinomas in histological type and grade. 
There were 50 samples in total distributed into 
two groups as: invasive ductal carcinoma (grade 1 
(n = 4), 2 (n = 9) or 3 (n = 21)), and invasive 
lobular carcinoma (mixed (tubulolobular) 
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Table1.  Primary antibodies used for immunohistochemistry. 
 
carcinoma grade 2 (n = 1), lobular carcinoma (n = 
12), and pleomorphic lobular carcinoma grade 3 
(n = 3)). 
Blocks of breast lesions were serially sectioned at 
five µm-thicknesses and stained with hematoxylin-
eosine or used for immunohistochemical 
techniques. 
 
Immunohistochemical Methods 
 
 Slices were deparaffinized and rehydrated 
tissue sections were treated for 30 min with 
hydrogen peroxide 0.3% in phosphate-buffered 
saline (PBS) pH 7.4, to block endogenous 
peroxidase, antigen unmasking was performed 
with pepsin (15 min, Sigma R2283). To minimize 
nonspecific binding, sections were incubated with 
serum blocking solution (Histostain® Bulk Kit, 
Invitrogen Corporation, Carlsbad, California) and 
subsequently incubated overnight with primary 
antibodies in a moist chamber at 4ºC. Information 
on primary antibodies is provided in Table 1. 
 The second day, immunohistochemistry was 
performed with standard procedures using 
Histostain® Bulk Kit (Invitrogen Corporation, 
Carlsbad, California). After immunoreactions, 
sections were counter-stained with Harris 
hematoxylin, dehydrated in ethanol, and mounted 
in a synthetic resin (Depex, Serva, Heidelberg, 
Germany). The specificity of the 
immunohistochemical procedures was checked 
by incubation of sections with nonimmune serum 
instead of the primary antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Clinical Methods 
 
 ER, PR, Ki67, and p53 were evaluated by the 
pathologist visually, providing a semi-quantitative 
estimate of the percentage of positive cells.  
 
Image Analysis  
 
 To establish the immunostaining percentage 
area of Nm23 and LPA1, ten digital images were 
acquired for each slide. To determinate the 
threshold values that discriminated the 
immunostaining from the counterstain and 
background, the red-green-blue (RGB) color 
mode values were converted to HSI values using 
MetaMorph software (Leica MMAF 1.4). The HSI 
system is thought to offer a much closer 
approximation to the behavior of human color 
vision than do untransformed RGB values [11]. 
 We next defined the ‘‘negative-chromaticity 
subdomain’’ following the methodology described 
by Maximova et al. (2006) [12]. Finally, we defined 
a positive-chromaticity subdomain—a set of HSI 
threshold value ranges selected such that no pixel 
with the negative-control hue would confound the 
identification of positively stained areas. 
 
Statistical Analisis 
 
 Statistical analysis was conducted using 
Pearson’s correlation coefficient test. Differences 
were considered significant when p < 0.001. 
Missing data were removed in pairs. The software 
used was Excel 2010 version 14.0.6 (SP1) 
Antigen Concentration Supplier Source 
Nm23-H1 1:100 
NOVUS BIOLOGICALS 
Litttleton. 
USA 
ER (estrogen receptor) Ready to use 
DAKO 
Carpinteria, California. 
USA 
PR (progesterone 
receptor) Ready to use 
DAKO 
Carpinteria, California. 
USA 
Ki67 Ready to use 
DAKO 
Carpinteria, California. 
USA 
p53 Ready to use 
DAKO 
Carpinteria, California. 
USA 
Monoclonal 
LPA1(EDG2) 1:100 
NOVUS BIOLOGICALS 
Litttleton. 
USA 
Polyclonal 
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(Microsoft Corporatio. Redmond, Washington, 
USA). 
 
RESULTS 
 
Qualitative results 
 
 Nm23 expression was strongly detected in 
epithelial cytoplasm of normal acini. Epithelial 
cells that had lost their normal histological 
structure also showed Nm23 staining (figs. 1a,b). 
LPA1 expression was identified at epithelial 
cytoplasm as occurred with Nm23, but in this 
case, immunostaining was weaker (figs. 1c-d). 
 Immunoreactivity to p53 was identified in 
cytoplasm and nuclear epithelial cells from all 
samples studied (figs. 2a,b). Nuclear p53 
immunostaining was also remarkable in the acini 
with histological changes (fig. 2b). Ki67 
immunoreactivity was observed in the nuclei of 
epithelial cells of the acini. There were two types 
of Ki67 staining: homogeneous nuclear staining, 
and granular staining. The first one was more 
intensive than the second one (fig. 3).  
 ER and PR immunoexpression was found in 
the nuclei of epithelial cells from all samples 
studied (figs. 4a,b).  
 
Figure1. Nm23 immunostaining (a,b) and LPA1 (c,d) x200. 
a: Acini with the cytoplasm immunostaining for Nm23. b: 
Tumour region intensely inmunostaining. c: Immunopositive 
acini for LPA1. d: Unstructured epithelium with LPA1 
immunorexpression in the cytoplasm. 
a b 
Figure2. p53 expression x200. a: Diffuse expression was observed in the cytoplasm of 
epithelial cells. b: Intense nuclei immunostaining. 
Figure3. Ki67 Inmunoxpresión x200. The 
image showed epithelial nuclear staining. 
Figure4. Hormone Receptor nuclear immunostaining x200. a: Positive 
immunohistochemical reaction for ER. b: Positive immunoexpression 
for PR.
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Quantitative results  
 
 All cases were classified en two huge groups 
attending hormonal receptors immunoexpression 
into Invasive Ductal Carcinoma (IDC), and 
Invasive Lobular Carcinoma (ILC). 
 
Invasive Ductal Carcinoma (IDC): 
 
Groups of patients without positive hormonal 
receptors: In this group (n=7), 6 cases were 
Nm23-positive. The Nm23 index ranged between 
2 and 97%, averaging 28.51%. LPA1 expression 
was found in 5 cases. LPA1 index ranged 
between 0 and 43%, averaging 8.15%. All cases 
were immunopositive to Ki67. The Ki67 averaging 
was 25.57% and Ki67 index ranged between 18 
and 35%. p53 immunoexpression was observed 
in 2 cases, but index range were wide, between 0 
and 95%, averaging 2.57%(Tables 2,3).  
 
Patient with ER positive: Only one case was ER+ 
and PR-. All immunohistochemistry done were 
positive (see Tables 2,3). This group was not 
taken part in the study of correlations.   
 
Patient with PR positive: Only one case was PR+ 
and ER-. As in the previous case, all markers 
were positive (Tables 2,3). This group neither 
formed part of the analysis of correlations. 
 
Groups of patients with positive hormonal 
receptors: This group was the biggest (n=25), 23 
cases were Nm23-positive. The Nm23 index 
ranged between 0 and 95%, averaging 42.08%. 
LPA1 expression was found in 17 cases. LPA1 
index ranged between 0 and 63%, averaging 
9.06%. All cases were immunopositive to Ki67. 
The Ki67 averaging was 15.64% and Ki67 index 
ranged between 10 and 25%. p53 
immunoexpression was observed in 13 cases, 
index range between 0 and 95%, averaging 
18%(Tables 2,3).  
 
Invasive Lobular Carcinoma (ILC): 
 
Groups of patients without positive hormonal 
receptors: No patients were included in this group 
(Tables 2,3).  
 
Patient with ER positive: Only one case was ER+ 
and PR-. All immunohistochemistry done were 
positive (Tables 2,3). This group was not taken 
part in the study of correlations.   
 
Patient with PR positive: No patients were 
included in this group (see Tables 2,3). 
 
Groups of patients with positive hormonal 
receptors: In this group (n=15), 13 cases Nm23 
positive, 13 cases LPA1 positive, 15 cases Ki67 
positive, and 3 cases p53 positive were observed. 
The Nm23 index ranged between 0 and 94%, 
averaging 33.45%. LPA1 index ranged between 0 
and 80%, averaging 13.97%. The Ki67 averaging 
was 11.2% and Ki67 index ranged between 7 and 
13%. p53 index range between 0 and 2%, 
averaging 04%(Tables 2,3).  
 
Table2.  Relationship between marker positivity and 
carcinomas classified according to hormonal receptors 
expression.   
 
Ratio of positives cases 
Carcinoma 
Group of 
patients 
Nm23 LPA1 Ki67 p53 
ER- PR- 6/7 5/7 7/7 2/7 
ER+ PR- 1/1 1/1 1/1 1/1 
ER- PR+ 1/1 1/1 1/1 1/1 
IDC 
ER+ PR+ 22/25 17/25 25/25 13/25 
ER- PR- 0/0 0/0 0/0 0/0 
ER+ PR- 1/1 1/1 1/1 1/1 
ER- PR+ 0/0 0/0 0/0 0/0 
ILC 
ER+ PR+ 13/15 13/15 15/15 3/15 
Invasive Ductal Carcinoma (IDC), and Invasive Lobular 
Carcinoma (ILC). 
 
Nm23 protein expression and its correlation 
with the clinicopathology variables 
 
 Correlation between Nm23 and LPA1 and 
traditional prognostic markers in breast carcinoma 
was done, as well as Nm23/LPA1 and 
clinicopathology variables. Groups with 1 or 0 
patients were eliminated. Only significant 
differences were found in Nm23/LPA1 and p53 in 
IDC ER- PR-.  Pearson correlation coefficient is 
showed in Tables 4 and 5 and figures 5-7. 
 
DISCUSSION 
 
 Several authors have been reported that ILC 
has characteristics and behaviors that are 
different from IDC [13;14], but it is unclear which 
of the two types showed better prognosis [15;16]. 
Therefore, in this study breast carcinoma samples 
had been separated into these two groups. After 
that, samples were classified attending the  
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Table3.  Relationship between marker positivity and carcinomas classified according to hormonal receptors expression.   
Nm23 (%) LPA1 (%) Ki67 (%) p53 (%) 
Carcinoma 
Group of 
patients 
Range Mean Range Mean Range Mean Range Mean 
ER- PR- 2-97 28.51 0-43 8.15 18-35 25.57 0-95 2.57 
ER+ PR- 3 - 6 - 15 - 85 - 
ER- PR+ 75 - 16 - 10 - 5 - 
IDC 
ER+ PR+ 0-95 42.08 0-63 9.06 10-25 15.64 0-95 18 
ER- PR- - - - - - - - - 
ER+ PR- 1 - 3 - 30 - 30 - 
ER- PR+ - - - - - - - - 
ILC 
ER+ PR+ 0-94 33.45 0-80 13.97 7-13 11.20 0-2 0.4 
Invasive Ductal Carcinoma (IDC), and Invasive Lobular Carcinoma (ILC). 
 
Table4.  Pearson correlation coefficients of Nm23 versus traditional prognostic markers in breast carcinoma.   
IDC ILC 
ER- PR- ER+ PR+ ER+ PR+ 
 
r Sig. r Sig. r Sig. 
LPA1 -0,351 p=0,441 -0,2335 p= 0,261 -0,3624 p= 0,184  
Ki67 -0,5185 p=0,233 -0,03895 p= 0,853 -0,06334 p= 0,822  
p53 0,7407 p=0,057 0,2764 p= 0,181 0,3810 p= 0,161  
r: Correlation, Sig.: significance; IDC: Invasive Ductal Carcinoma, and ILC: Invasive Lobular Carcinoma. 
 
Table5.  Pearson correlation coefficients of Nm23/LPA1 versus traditional prognostic markers in breast carcinoma.   
IDC ILC 
ER- PR- ER+ PR+ ER+ PR+ 
 
r Sig. r Sig. r Sig. 
Ki67 -0,4565 p= 0,303 -0,05506 p= 0,798 -0,05356 p=0,849 
p53 0,9707 p<0.001 -0,1242 p= 0,563  0,3612 p=0,186  
r: Correlation, Sig.: significance; IDC: Invasive Ductal Carcinoma, and ILC: Invasive Lobular Carcinoma. 
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hormonal status of the patient. In 2005, the 
Committee of Consensus on Adjuvant Treatments 
for Breast Cancer at an Early Stage 
recommended that the first consideration in 
selecting the type of treatment should be the 
endocrine responsiveness. The recognition of this 
fact increased the relevance of pathologic 
evaluation as to the biological information [17]. 
 For this reason the estrogen receptor has 
been the most extensively studied prognostic 
indicator to date. Orvieto et al. (2002) and Kasami 
et al. (2008) [18;19] have reported a positive 
relationship between estrogen receptor, increased 
disease-free interval and better survival of 
patients. The estrogen and progesterone 
receptors are currently the most widely used 
predictive factors for the choice of hormonal 
treatment [17].  
  
 
 
 
 
 
 
 
 
 
 
 
Figure5. Dispersion graphs for %Nm23 and %LPA1. The three groups studied showed an inverse trend. IDC: Invasive 
Ductal Carcinoma; ILC: Invasive Lobular Carcinoma; ER: Estrogen Receptors, and PR: Progesterone Receptors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure6. Dot plots for %Nm23 and %p53. All groups showed positive correlation, but not significant different was 
detected. IDC: Invasive Ductal Carcinoma; ILC: Invasive Lobular Carcinoma; ER: Estrogen Receptors, and PR: 
Progesterone Receptors. 
 
  
 
 
 
 
 
 
Figure7. Dot plots for %Nm23 and %Ki67. Negative correlation was observed in studied groups. IDC: Invasive Ductal 
Carcinoma; ILC: Invasive Lobular Carcinoma; ER: Estrogen Receptors, and PR: Progesterone Receptors. 
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Antimetastatic genes, such as Nm23, play an 
important role in the porgression of breast cancer 
[20]. Several researchers have observed the 
probable inverse association of Nm23 expression 
with disease prognosis and/or metastasis [21]. 
Metastatic process involves activation and down 
regulation of multiple genes at each step of 
metastatic cascade [4]. Nm23 expression has 
been widely studied in various cancers and with 
their relation to staging and prognosis. Bal A et al. 
(2008) [4] results implicate that lack of Nm23 
expression in early lesions may be predictive of 
progression to invasive carcinoma and thus could 
be helpful in predicting the aggressiveness of the 
disease. 
 In mestastatic cascade are implicated a 
number of molecules such as LPA1. Horak et al. 
(2007) [22] demostrated by in vitro  studies, an 
inverse correlation between Nm23 and LPA1 . 
They observed in vivo that LPA1 could play an 
importan role in the promotion of metastasis. In 
our work, Pearson correlation coefficients Nm23 
versus LPA1 were negative in all groups 
analysed. Not significant differences were 
detected probably because sample size was not 
enough big. However, the relationship between 
Nm23 and LPA1 showed an inverse correlation, 
as described Horak et al. (2007) [22]. 
 p53 is the most frequently mutated gene in 
human cancer and is the founding member of the 
p53 family. In response to various cellular 
stresses, p53 regulates a variety of cellular 
functions including cell cycle progression, 
apoptosis, senescence, cell motility, DNA repair, 
genetic instability and cell metabolism by 
transcriptionally activating a variety of cellular 
genes [23-25]. Jung et al. (2007) [25] showed that 
Nm23-H1 and its binding partner STRAP (serine-
threonine kinase receptor-associated protein) 
interacted with p53 and potentiated p53 activity. 
Both NM23-H1 and STRAP directly interacted 
with the central DNA binding domain within 
residues 113-290. The use of Nm23-H1 and 
STRAP mutants revealed that Cys(145) of Nm23-
H1 and Cys(152) or Cys(270) of STRAP were 
responsible for p53 binding. Furthermore, 
Cys(176) and Cys(135) of p53 were required to 
bind Nm23-H1 and STRAP, respectively.  
 There is no consensus on expression of p53 
when studying different carcinomas. Some 
authors associated p53 with a poor disease 
prognosis [26] and others with a high survival and 
good response to the treatment [27]. Simone et al. 
(2001) [28] found a positive correlation between 
presences of p53 with that of Nm23 histological 
samples, but Midulla el at. (1999) [29] were not 
observed any correlation within these two 
markers. This study is accorded with Jung et al. 
(2007) [25] and Simone et al. (2001) [28]. Note 
that the ratio Nm23/LPA1 was statistically 
significant for the group IDC ER- PR-. Maybe 
LPA1 plays an opposite role in p53 expression. In 
this regard, Hurst-Kennedy et al. (2009) [30] 
showed in an in vitro study with chondrocytes that 
LPA1 prevented apoptotic signalling by 
decreasing the abundance, nuclear localization, 
and transcriptional activity of the tumour-
suppressor p53.  
 Ki67 is expressed in G1-, S-, G2 and mitosis 
phase. Nm23 has been correlation inversely with 
Ki67 in melanoma of the oral cavity and bladder 
tumour, showing a low expression of Ki67 in 
benign tissues and high expression of Nm23 in 
this tumour type [31]. Also, decrease of Nm23 
expression, but not Ki-67, was significantly 
correlated with lymph node metastasis of breast 
invasive ductal carcinoma [32]. In all cases 
studied, there is an inverse correlation between 
Nm23 or Nm23/LPA1 and Ki67, although none of 
them was significant.  
 In summary, it can be concluded that: 1) 
Nm23 and LPA1 tend to be inversely correlated; 
2) Nm23 correlates positively with p53, regardless 
of tumour type and patient’s hormonal status; 3) 
Nm23 shows a reverse trend in comparison with 
Ki67. However, more studies are needed to 
determinate if hormone receptors play some role 
in the inverse relationship between Nm23-LPA1 
and to know the tumour type implication in these 
relationships. 
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